Dr Beshir is a genomic epidemiologist with a background in Biology, Medical Parasitology and Biomedical Science.
Dr Beshir's research work focuses on understanding how malaria parasites evade drug attack (become resistant) and escape detection by rapid diagnostic tests (RDTs)and become undetectable. To achieve this, we continuously work on the development of new and fit-for-purpose molecular and genomic tools to detect and monitor these new malaria parasite population. Dr Beshir has previously worked on the development of affordable COVID-19 testing assays that can be used in Low and Middle Income Countries, and supported LMIC countries with COVID-19 vaiant detections using NGS genomics.
Dr Beshir previously worked on EDCTP-funded WANECAM project on Clinical trial of four Artemisinin Combination Therapies (ACT) in west Africa. Dr Beshir also worked on molecular evaluation of the efficacy of ACTs as well as Seasonal Malaria Chemoprevention (SMC) therapies in West Africa. In both projects, Dr Beshir worked on development of new molecular tools to monitor the emergence of drug resistance parasites to both ACTs and SMCs.
Dr Beshir is also involved in teaching both within LSHTM and externally, and supervision of MSc and PhD students. Dr Beshir is also a member of LSHTM ethics commitee and member of EDI in ITD Faculty.
Dr Beshir completed his PhD in Prof Sutherland's group.
Dr Beshir's research work focuses on understanding how malaria parasites evade drug attack (become resistant) and escape detection by rapid diagnostic tests (RDTs)and become undetectable. To achieve this, we continuously work on the development of new and fit-for-purpose molecular and genomic tools to detect and monitor these new malaria parasite population. Dr Beshir has previously worked on the development of affordable COVID-19 testing assays that can be used in Low and Middle Income Countries, and supported LMIC countries with COVID-19 vaiant detections using NGS genomics.
Dr Beshir previously worked on EDCTP-funded WANECAM project on Clinical trial of four Artemisinin Combination Therapies (ACT) in west Africa. Dr Beshir also worked on molecular evaluation of the efficacy of ACTs as well as Seasonal Malaria Chemoprevention (SMC) therapies in West Africa. In both projects, Dr Beshir worked on development of new molecular tools to monitor the emergence of drug resistance parasites to both ACTs and SMCs.
Dr Beshir is also involved in teaching both within LSHTM and externally, and supervision of MSc and PhD students. Dr Beshir is also a member of LSHTM ethics commitee and member of EDI in ITD Faculty.
Dr Beshir completed his PhD in Prof Sutherland's group.
Affiliations
Department of Infection Biology
Faculty of Infectious and Tropical Diseases
Centres
Malaria Centre
Teaching
Dr Beshir teaches molecular and genomic evolution, and he is a tutor on Medical Parasitology course and Malaria DL module. Dr Beshir is involved in teaching of Miscroscopic Diagnosis of Malaria Parasites and Molecular Biology. Dr Beshir is a member of joint committee for Medical Parasitology and Medical Entomology for Disease Control courses.
Research
Research Area
Drug resistance
Diagnostics
Molecular epidemiology
Genomics
Disease and Health Conditions
Malaria
COVID-19
Country
Somalia
Yemen
Eritrea
Sudan
Nigeria
Burkina Faso
Cameroon
Ghana
Ethiopia
Tanzania
Cote d'Ivoire
Benin
Democratic Republic of the Congo
Mali
Guinea
Region
Sub-Saharan Africa (all income levels)
Selected Publications
2024
PLoS medicine
2023
Clinical Infectious Diseases
2023
Genome medicine
2023
medRxiv
Estimating the impact of Plasmodium falciparum dhfr and dhps mutations on protective efficacy of sulfadoxine-pyrimethamine: evidence from therapeutic efficacy studies and implications for malaria chemoprevention
2023
72st Annual Meeting of the American Society of Tropical Medicine and Hygiene
2023
The Journal of antimicrobial chemotherapy
2022
The Lancet Infectious diseases
2022
ASTMH Annual Meeting
2022
Parasite epidemiology and control
2022
Malaria journal